Tag: pegfilgrastim biosimilars market trends.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Pegfilgrastim Biosimilars Market Grown from 2024 to 2025?

The market size for pegfilgrastim biosimilars has seen an accelerated growth in the past few years. It is projected to increase from $1.56 billion in 2024 to $1.8 billion in 2025, representing a compound annual growth rate (CAGR) of 15.3%. The remarkable expansion in the historical period is due to several factors including higher cancer incidence rates, government interventions, augmenting healthcare spending, boost in biopharmaceutical R&D expenditures, lower prices of biosimilars, and widespread use of these biosimilar medications.

What Growth Rate Is Anticipated for the Pegfilgrastim Biosimilars Market in the Coming Years?

In the coming years, the pegfilgrastim biosimilars market is projected to experience fast-paced expansion, with its value estimated to reach $3.44 billion in 2029, growing at a compound annual growth rate (CAGR) of 17.5%. This predicted growth during the forecast timeframe can be ascribed to the escalating prevalence of cancer, older demographic, a rise in the number of approvals, as well as targets and incentives. Major trends for the forecast period includes exploiting more liberal regulations for the creation of advanced biosimilars, substantial investment in R&D for the production of innovative and efficient biologics, strong emphasis on fostering strategic collaborations with major players to broaden their R&D activities in new medication developments, and an increased focus on mergers and acquisitions to broaden both their customer base and regional markets. There is also an increasing focus on the production of biosimilars for neutropenia treatment to enhance revenue and product portfolio.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=4015&type=smp

Who Are the Leading Companies in the Pegfilgrastim Biosimilars Market?

Major companies operating in the pegfilgrastim biosimilars market include Amgen, Mylan N.V., Sandoz (a Novartis division), Teva Pharmaceutical Industries Ltd., Biocon, Pfizer, Celltrion Healthcare, Coherus BioSciences, Gedeon Richter, Fresenius Kabi, Hetero Labs, Intas Pharmaceuticals, LG Chem, Merck KGaA, Zydus Cadila, Aurobindo Pharma, Apotex Inc., Dr. Reddy’s Laboratories, Stada Arzneimittel AG, Reddy’s Laboratories, Shanghai Henlius Biotech, Alvotech, EirGenix, Bharat Biotech, Kye Pharmaceuticals, CinnaGen, Boryung Pharmaceutical, Sinopharm

What Are the Key Drivers of the Pegfilgrastim Biosimilars Market?

The pegfilgrastim biosimilars market is likely to be propelled by government efforts aimed at promoting biosimilars. Recognizing their affordability, governments globally are shifting their attention towards the growth of biosimilars. To expand treatment alternatives, the US Food and Drug Administration (FDA) implemented a Biosimilar Action Plan. The Australian government has pledged its support for the Biosimilar Awareness Initiative, bolstering their commitment by assisting the Generic and Biosimilar Medicines Association with a grant worth $5 million. This pledge supports widespread education on biosimilars and activities encouraging appropriate distribution, prescription, and utility of such medicines. Therefore, these governmental strategies aimed at biosimilar development contribute to heightening production and awareness, subsequently fostering the advancement of the pegfilgrastim biosimilars market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=4015&type=smp

What Are the Key Market Segments in the Pegfilgrastim Biosimilars Industry?

The pegfilgrastim biosimilars market covered in this report is segmented –

1) By Application: Chemotherapy Treatment, Transplantation, Other Applications

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies

Subsegments:

1) By Chemotherapy Treatment: Supportive Care for Cancer Patients, Reduction of Chemotherapy-Induced Neutropenia

2) By Transplantation: Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation

3) By Other Applications: Treatment of Chronic Neutropenia, Treatment of Severe Congenital Neutropenia, Other Supportive Therapies in Oncology

What Are the Latest Trends in the Pegfilgrastim Biosimilars Market?

Firms in the pegfilgrastim biosimilar market are escalating their product creativity through essential collaborations. In a bid to remain relevant in the increasingly cutthroat market, firms are crafting innovative products and pooling resources and knowledge with other firms. The long-standing trend of synergy with academic and research bodies via partnerships or out-licensing contracts has surged in recent years within this market. A case in point is the partnership in May 2023, between Amneal Pharmaceuticals and Kashiv Biosciences, American companies in the generics and specialty pharmaceutical and biosciences sectors respectively. Together, they engineered and launched Fylnetra (pegfilgrastim-pbbk), a biosimilar pegfilgrastim. FYLNETRA, a preservative-free, transparent solution dispensed in a 6 mg/0.6 mL single-use prefilled syringe, is used to curb the risks of infection, notably febrile neutropenia, among patients with non-myeloid cancers undertaking certain myelosuppressive anti-cancer procedures.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/pegfilgrastim-biosimilar-global-market-report

What Are the Key Regional Markets in the Pegfilgrastim Biosimilars Industry?

North America was the largest region in the pegfilgrastim biosimilars market in 2024. Middle East is expected to be the fastest growing region in the global pegfilgrastim biosimilars market share during the forecast period. The regions covered in the pegfilgrastim biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=4015

This Report Delivers Insight On:

1. How big is the pegfilgrastim biosimilars market, and how is it changing globally?

2. Who are the major companies in the pegfilgrastim biosimilars market, and how are they performing?

3. What are the key opportunities and risks in the pegfilgrastim biosimilars market right now?

4. Which products or customer segments are growing the most in the pegfilgrastim biosimilars market?

5. What factors are helping or slowing down the growth of the pegfilgrastim biosimilars market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the pegfilgrastim biosimilars industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

#What is the Projected CAGR for the Pegfilgrastim Biosimilars Market Size from 2025 to 2034?

The market size of pegfilgrastim biosimilars has quickly expanded in the past few years. This growth is projected to rise from $1.56 billion in 2024 to approximately $1.8 billion in 2025, with a compound annual growth rate (CAGR) of 15.3%. Factors contributing to this growth during the historical period include a higher prevalence rate of cancer, governmental initiatives, an increase in healthcare spending, a rise in biopharmaceutical R&D expenses, the affordability of biosimilars, and a significant penetration rate of biosimilar drugs.

The market for pegfilgrastim biosimilars is projected to exhibit swift expansion in the coming years, surging to $3.44 billion by 2029 with a compound annual growth rate (CAGR) of 17.5%. Factors contributing to the expected growth during this forecast period include the rising incidence of cancer, an aging demographic, an increase in approvals, and overarching targets and incentives. Expected trends throughout the same period are to capitalize on less stringent regulations to innovate new and better biosimilars, significant investments towards research and development for creating more efficient and groundbreaking biologics, pursuing strategic collaborations with significant players for broadening research and development pursuits in new drug development, intensifying focus on growth strategies related to mergers and acquisitions for widening customer reach and geographical market presence, and amplifying the focus on the manufacture of biosimilars for treating neutropenia with the goal to enhance revenues and product offerings.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=4015&type=smp

How Are Key Drivers in the Industry Acting as Catalysts for the Growth of thePegfilgrastim Biosimilars Market?

The pegfilgrastim biosimilars market is likely to be stimulated by government efforts focused on biosimilar development. Globally, governments are turning their focus towards biosimilars as they are economical. The Biosimilar Action Plan, launched by the US Food and Drug Administration (FDA), aims to expand treatment options. Likewise, the Australian government’s advocacy for the Biosimilar Awareness Initiative has been fortified by backing the Generic and Biosimilar Medicines Association with a $5 million grant, promoting increased general awareness and activities related to appropriate dispensing, prescribing and usage of biosimilar medicines. Therefore, these governmental movements towards the development of biosimilars positively contribute to the expansion and awareness, consequently bolstering the growth of the pegfilgrastim biosimilars market.

Which Segments in the Pegfilgrastim Biosimilars Offer the Most Growth?

The pegfilgrastim biosimilars market covered in this report is segmented –

1) By Application: Chemotherapy Treatment, Transplantation, Other Applications

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies

Subsegments:

1) By Chemotherapy Treatment: Supportive Care for Cancer Patients, Reduction of Chemotherapy-Induced Neutropenia

2) By Transplantation: Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation

3) By Other Applications: Treatment of Chronic Neutropenia, Treatment of Severe Congenital Neutropenia, Other Supportive Therapies in Oncology

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=4015&type=smp

What Are the Fastest-Growing Geographies in the #How Are Key Drivers in the Industry Acting as Catalysts for the Growth of thePegfilgrastim Biosimilars Market?# Market?

North America was the largest region in the pegfilgrastim biosimilars market in 2024. Middle East is expected to be the fastest growing region in the global pegfilgrastim biosimilars market share during the forecast period. The regions covered in the pegfilgrastim biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Are the Current Market Growth and Trends in the Pegfilgrastim Biosimilars Industry?

In a drive for product innovation, firms within the pegfilgrastim biosimilar market are expanding their strategic collaborations. To maintain their position in the competitive market, these companies are focusing on the development of innovative products and an exchange of skills and expertise with peers. The pattern of fostering collaboration between companies and academic or research institutions through partnerships or out-licensing tactics in this market has seen a rise in recent years. To illustrate this, in May 2023, a partnership was formed between Amneal Pharmaceuticals, a generics and specialty pharmaceutical firm based in the US, and Kashiv Biosciences, an integrated biosciences company also based in the US. The collaboration aimed to develop and launch Fylnetra (pegfilgrastim-pbbk), a biosimilar pegfilgrastim. Fylnetra, a clear, preservative-free solution packed in a 6 mg/0.6 mL single-dose prefilled syringe, is intended to curtail the risk of infections, distinctly febrile neutropenia, in non-myeloid cancer patients undergoing specific myelosuppressive anti-cancer treatments.

View the full report here:

https://www.thebusinessresearchcompany.com/report/pegfilgrastim-biosimilar-global-market-report

What Are the Key Elements That Define the Pegfilgrastim Biosimilars Market?

Pegfilgrastim biosimilars refer to a biosimilar that is intended to be used in conjunction with supportive care for people with non-myeloid cancer. It can help prevent or treat infections brought on by myelosuppressive chemotherapy by promoting the formation of certain white blood cells.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=4015

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

Which Primary Drivers Are Supporting the Continued Market Growth of thePegfilgrastim Biosimilars Market?

Initiatives put in place by various governments for the advancement of biosimilars are predicted to prop up the pegfilgrastim biosimilars market. Governments across the globe are promoting biosimilar development due to its cost-effective traits. The launch of the Biosimilar Action Plan by the United States Food and Drug Administration (FDA) is an endeavor to increase the available treatment options. The Australian government is solid in its dedication to the Biosimilar Awareness Initiative, and further strengthened its commitment by extending a $5 million grant to the Generic and Biosimilar Medicines Association. This funding supports expanded basic biosimilar education and activities that encourage their appropriate dispensing, prescription, and use. Therefore, these government-driven initiatives are pivotal to boosting the production and awareness of biosimilars, ultimately fostering the growth of the pegfilgrastim biosimilars market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=4015&type=smp

#What Growth Opportunities Will Drive the Pegfilgrastim Biosimilars Market’s CAGR Through 2034?

The market size for pegfilgrastim biosimilars has seen a swift expansion in the past few years. It’s projected to increase from $1.56 billion in 2024 to $1.8 billion in 2025, with a compound annual growth rate (CAGR) of 15.3%. This growth during the historical period can be tied to a rise in cancer cases, government programmes, higher healthcare spending, an increase in the expenditure on biopharmaceutical R&D, the affordable pricing of biosimilars, and widespread usage of biosimilar medicines.

In the coming years, the pegfilgrastim biosimilars market is projected to experience a significant expansion, predicted to reach $3.44 billion by 2029 with a solid compound annual growth rate (CAGR) of 17.5 percent. This considerable growth within the projection period can be credited to various factors like the escalating prevalence of cancer, an aging population, the rising number of approvals, as well as targets and incentives. Notable trends anticipated during this period encompass capitalizing on looser regulations to devise superior biosimilars, heavy investment in research and development for creatives and effective biologics, establishing strategic alliances with major market players to extend their research and development activities in new pharmaceutical advancements, heightening focus on growth strategies focused on mergers and acquisitions to widen customer base and geographic markets, and a growing emphasis on the production of biosimilars intended for neutropenia treatment to increase both revenue and product offerings.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=4015

How Are Consumer Market Innovations Shaping the Current and Future Landscape of thePegfilgrastim Biosimilars Market?

Firms within the pegfilgrastim biosimilar market are stepping up their product innovation through strategic alliances. In order to stay afloat in the intensifying market competition, businesses are crafting innovative items and collaborating with others to share abilities and knowledge. Historically, these companies have maintained collaborations with academic and research entities in this market via partnerships or out-licensing agreements, but this practice has seen an uptick in recent years. For example, in May 2023, Amneal Pharmaceuticals, a generic and specialty pharmaceutical company located in the United States, established a partnership with Kashiv Biosciences, a US-based integrated biosciences firm, to create and launch Fylnetra (pegfilgrastim-pbbk), a biosimilar pegfilgrastim. FYLNETRA, an unpreserved, transparent solution provided in a 6 mg/0.6 mL single-dose prefilled syringe, is utilized to mitigate infection risks, specifically febrile neutropenia, in patients with non-myeloid cancers who are undergoing certain myelosuppressive anti-cancer treatments.

Who Are the Key Market Players Influencing the Growth of the Corn and Pegfilgrastim Biosimilars Industry?

Major companies operating in the pegfilgrastim biosimilars market include Amgen, Mylan N.V., Sandoz (a Novartis division), Teva Pharmaceutical Industries Ltd., Biocon, Pfizer, Celltrion Healthcare, Coherus BioSciences, Gedeon Richter, Fresenius Kabi, Hetero Labs, Intas Pharmaceuticals, LG Chem, Merck KGaA, Zydus Cadila, Aurobindo Pharma, Apotex Inc., Dr. Reddy’s Laboratories, Stada Arzneimittel AG, Reddy’s Laboratories, Shanghai Henlius Biotech, Alvotech, EirGenix, Bharat Biotech, Kye Pharmaceuticals, CinnaGen, Boryung Pharmaceutical, Sinopharm

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/pegfilgrastim-biosimilar-global-market-report

Which Key Market Segments Comprise the Pegfilgrastim Biosimilars Market and Drive Its Revenue Growth?

The pegfilgrastim biosimilars market covered in this report is segmented –

1) By Application: Chemotherapy Treatment, Transplantation, Other Applications

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies

Subsegments:

1) By Chemotherapy Treatment: Supportive Care for Cancer Patients, Reduction of Chemotherapy-Induced Neutropenia

2) By Transplantation: Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation

3) By Other Applications: Treatment of Chronic Neutropenia, Treatment of Severe Congenital Neutropenia, Other Supportive Therapies in Oncology

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=4015&type=smp

Which Regions Are Emerging as Leaders in the Pegfilgrastim Biosimilars Market?

North America was the largest region in the pegfilgrastim biosimilars market in 2024. Middle East is expected to be the fastest growing region in the global pegfilgrastim biosimilars market share during the forecast period. The regions covered in the pegfilgrastim biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Reports Similar to the Global Pegfilgrastim Biosimilars Market 2025, By The Business Research Company:

Anesthesia Disposables Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/anesthesia-disposables-global-market-report

Hearing Aid Devices And Equipment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/hearing-aid-devices-and-equipment-global-market-report

Cancer Vaccines Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cancer-vaccine-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the pegfilgrastim biosimilars market size evolved in recent years?

In recent years, the market size for pegfilgrastim biosimilars has experienced swift expansion. The expectations are for it to rise from $1.56 billion in 2024 to reach $1.8 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 15.3%. The historic growth of this sector is primarily due to factors such as higher incidence of cancer, government policy initiatives, elevated healthcare spending, increased investment in biopharmaceutical research and development, the affordability of biosimilars, and extensive usage of these biosimilar drugs.

What are the predictions for the pegfilgrastim biosimilars market size in the coming years?

The market size of medical device outsourcing is projected to experience swift expansion in the forthcoming years. It is estimated to reach up to $290.76 billion in 2029 at a compound annual growth rate (CAGR) of 15.6%. The surge during the projected period is due to the concentration on core competencies, reduction in time-to-market requirements, cost-effectiveness in manufacturing, need for scalability and flexibility, and the growing intricacy of medical devices. Notable trends expected in this period encompass the increase in customization and personalization, emphasis on risk reduction and compliance, escalating demand for remote monitoring devices, heightened focus on data security, and innovative advancements in wearable medical devices.

Get your pegfilgrastim biosimilars market report here!

https://www.thebusinessresearchcompany.com/report/pegfilgrastim-biosimilar-global-market-report

What key factors are fueling the growth of the pegfilgrastim biosimilars market?

Initiatives undertaken by the government to facilitate the growth of biosimilars, are projected to propel the pegfilgrastim biosimilars market. Governments around the world are putting an emphasis on biosimilar development, spurred by their affordability. The US Food and Drug Administration (FDA), for instance, initiated a Biosimilar Action Plan to expand treatment alternatives. The Australian government has shown dedication to the Biosimilar Awareness Initiative and further bolstered their commitment by financially supporting the Generic and Biosimilar Medicines Association with a grant worth $5 million. This step is aimed at fostering a broader understanding of biosimilars and encouraging the appropriate prescription, dispensing, and use of these medicines. As a result, such government-led efforts for the promotion and development of biosimilars contribute to both increased manufacturing and awareness, which somehow stimulates the expansion of the pegfilgrastim biosimilars market.

How is the global pegfilgrastim biosimilars market divided into key segments?

The pegfilgrastim biosimilars market covered in this report is segmented –

1) By Application: Chemotherapy Treatment, Transplantation, Other Applications

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies

Subsegments:

1) By Chemotherapy Treatment: Supportive Care for Cancer Patients, Reduction of Chemotherapy-Induced Neutropenia

2) By Transplantation: Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation

3) By Other Applications: Treatment of Chronic Neutropenia, Treatment of Severe Congenital Neutropenia, Other Supportive Therapies in Oncology

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=4015&type=smp

Who are the key firms paving the way for growth in the pegfilgrastim biosimilars market?

Major companies operating in the pegfilgrastim biosimilars market include Amgen, Mylan N.V., Sandoz (a Novartis division), Teva Pharmaceutical Industries Ltd., Biocon, Pfizer, Celltrion Healthcare, Coherus BioSciences, Gedeon Richter, Fresenius Kabi, Hetero Labs, Intas Pharmaceuticals, LG Chem, Merck KGaA, Zydus Cadila, Aurobindo Pharma, Apotex Inc., Dr. Reddy’s Laboratories, Stada Arzneimittel AG, Reddy’s Laboratories, Shanghai Henlius Biotech, Alvotech, EirGenix, Bharat Biotech, Kye Pharmaceuticals, CinnaGen, Boryung Pharmaceutical, Sinopharm

Which trends are expected to transform the pegfilgrastim biosimilars market?

Businesses in the pegfilgrastim biosimilar market are heightening their product ingenuity via cooperative collaborations. In an effort to remain relevant in an ever-growing competitive marketplace, these businesses are creating groundbreaking products and dividends their knowledge and proficiency with their counterparts. The trend of partnering or signing out-licensing deals with education and research institutions has been prevalent for some time in this market and has seen a significant rise recently. For example, in May 2023, a noteworthy collaboration was seen between Amneal Pharmaceuticals, a US-based generics, and specialty pharmaceutical firm, and Kashiv Biosciences, a US-based comprehensive biosciences business. The collaboration aimed at developing and launching Fylnetra (pegfilgrastim-pbbk), a biosimilar pegfilgrastim. FYLNETRA, a preservative-free, transparent solution, comes in a 6 mg/0.6 mL single-dose pre-filled syringe and helps lessen infection threats, particularly febrile neutropenia, in patients suffering from non-myeloid cancers who are undergoing specific myelosuppressive anti-cancer treatments.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=4015

What regions are contributing significantly to the growth of the pegfilgrastim biosimilars market?

North America was the largest region in the pegfilgrastim biosimilars market in 2024. Middle East is expected to be the fastest growing region in the global pegfilgrastim biosimilars market share during the forecast period. The regions covered in the pegfilgrastim biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Similar Reports By The Business Research Company:

Biosimilar Hormones Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/biosimilar-hormone-global-market-report

Oral Biologics & Biosimilars Global Market Opportunities And Strategies To 2030

https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-market

Rituximab Biosimilars Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/rituximab-biosimilar-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How Significant is the Anticipated Growth Rate of the Pegfilgrastim Biosimilars Market from 2025 to 2034?

The market size for pegfilgrastim biosimilars has seen rapid expansion in recent years. The market value is predicted to escalate from $1.56 billion in 2024 to $1.8 billion in 2025, with an annual growth rate (CAGR) of 15.3%. Factors that contributed to growth during the historical period include a rise in cancer prevalence, governmental actions, augmented healthcare spending, increased R&D expenditure in biopharmaceuticals, affordability of biosimilars, and widespread use of biosimilar drugs.

Over the next several years, the pegfilgrastim biosimilars market is predicted to experience accelerated growth. The market is projected to expand to $3.44 billion in 2029, with a compound annual growth rate (CAGR) of 17.5%. Factors contributing to this growth during the forecast period include a rise in the incidence of cancer, an older population, an increase in approvals, targets, and incentives. The period is likely to see trends such as leveraging less rigid regulations to create improved biosimilars, heavy investment in R&D for the production of efficient and creative biologics, a focus on forming strategic alliances with major players to broaden their R&D for new drug discoveries, growing their interest in M&A expansion tactics to increase their client base and geographical markets, and a heightened focus on the generation of biosimilars for neutropenia treatment to amplify revenues and product range.

How Are Key Drivers in the Industry Acting as Catalysts for the Growth of the pegfilgrastim biosimilars Market?

In the pegfilgrastim biosimilars market, support and development efforts from the government are expected to be a significant driving factor. Because of their affordability, biosimilars are the target of development initiatives from global governments. Launching the Biosimilar Action Plan, the US Food and Drug Administration (FDA) aimed to enhance the availability of treatment alternatives. The Australian government is backing the Biosimilar Awareness Initiative, which they have bolstered by allocating a $5 million grant to the Generic and Biosimilar Medicines Association. The purpose of this grant money is to support the enhancement of general biosimilar education, along with initiatives encouraging appropriate dispensation, prescription and usage of biosimilar medications. Therefore, government-driven developmental efforts around biosimilars can facilitate increased production, awareness and subsequently the growth of the pegfilgrastim biosimilars market.

Request Your Free Pegfilgrastim Biosimilars Market Report Sample Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=4015&type=smp

Who Are the Dominant Players Pushing the Boundaries of the Pegfilgrastim Biosimilars Market?

Major companies operating in the pegfilgrastim biosimilars market include:

• Amgen_x000D_

• Mylan N.V._x000D_

• Sandoz (a Novartis division)_x000D_

• Teva Pharmaceutical Industries Ltd._x000D_

• Biocon_x000D_

How Are Market Trends Revolutionizing the Pegfilgrastim Biosimilars Industry in Recent Times?

Strategic collaborations for product innovation are on the rise in the pegfilgrastim biosimilar market as corporates strive to remain competitive. Not only are they creating innovative products, but they are also pooling resources and skills with other companies. Though collaborations with academic and research institutions are not new, they’ve been ramping up in recent years with more partnerships and out-licensing deals. A case in point is the May 2023 collaboration between US-based Amneal Pharmaceuticals and Kashiv Biosciences to develop and launch Fylnetra (pegfilgrastim-pbbk), a biosimilar pegfilgrastim delivered in a 6 mg/0.6 mL single-dose prefilled syringe. Fylnetra, a preservative-free clear solution, is used to mitigate the risk of infection, specifically febrile neutropenia, in non-myeloid cancer patients undergoing specific myelosuppressive anti-cancer treatments.

Pre-order Your Report for Quick and Easy Delivery!

https://www.thebusinessresearchcompany.com/report/pegfilgrastim-biosimilar-global-market-report

Which Primary Segments of the Pegfilgrastim Biosimilars Market Are Driving Growth and Industry Transformations?

The pegfilgrastim biosimilars market covered in this report is segmented –

1) By Application: Chemotherapy Treatment, Transplantation, Other Applications

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies

Subsegments:

1) By Chemotherapy Treatment: Supportive Care for Cancer Patients, Reduction of Chemotherapy-Induced Neutropenia

2) By Transplantation: Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation

3) By Other Applications: Treatment of Chronic Neutropenia, Treatment of Severe Congenital Neutropenia, Other Supportive Therapies in Oncology

Which Geographic Areas Are Influencing the Growth of the Pegfilgrastim Biosimilars Market?

North America was the largest region in the pegfilgrastim biosimilars market in 2024. Middle East is expected to be the fastest growing region in the global pegfilgrastim biosimilars market share during the forecast period. The regions covered in the pegfilgrastim biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Are the Core Features That Define the Pegfilgrastim Biosimilars Market?

Pegfilgrastim biosimilars refer to a biosimilar that is intended to be used in conjunction with supportive care for people with non-myeloid cancer. It can help prevent or treat infections brought on by myelosuppressive chemotherapy by promoting the formation of certain white blood cells.

Browse Through More Similar Reports By The Business Research Company:

Biosimilar Hormones Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/biosimilar-hormone-global-market-report

Oral Biologics & Biosimilars Global Market Opportunities And Strategies To 2030

https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-market

Rituximab Biosimilars Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/rituximab-biosimilar-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: